Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...
Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast ...
Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...
As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p ...
Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 ...
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...
Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...
Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...
The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...
The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...
NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...